These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 9608857)

  • 1. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays.
    Benigni R; Bossa C; Tcheremenskaia O; Giuliani A
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):809-19. PubMed ID: 20438313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro carcinogenicity testing: present and future perspectives in pharmaceutical development.
    Kowalski LA
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):29-35. PubMed ID: 11727320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
    Kirkland D; Aardema M; Müller L; Makoto H
    Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
    Wells MY; Williams ES
    Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).
    Friedrich A; Olejniczak K
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):225-48. PubMed ID: 21513764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals.
    Contrera JF; Jacobs AC; DeGeorge JJ
    Regul Toxicol Pharmacol; 1997 Apr; 25(2):130-45. PubMed ID: 9185889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment?
    Doktorova TY; Pauwels M; Vinken M; Vanhaecke T; Rogiers V
    Crit Rev Toxicol; 2012 Feb; 42(2):91-106. PubMed ID: 22141324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxicity and carcinogenicity testing of pharmaceuticals: correlations between induction of DNA lesions and carcinogenic activity.
    Brambilla G; Mattioli F; Robbiano L; Martelli A
    Mutat Res; 2010; 705(1):20-39. PubMed ID: 20206292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotoxicity and carcinogenicity studies of antihistamines.
    Brambilla G; Mattioli F; Robbiano L; Martelli A
    Arch Toxicol; 2011 Oct; 85(10):1173-87. PubMed ID: 21327970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
    Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
    Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternatives to the carcinogenicity bioassay for toxicity prediction: are we there yet?
    Benigni R
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):407-17. PubMed ID: 22360376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.